Relief Therapeutics Holding AG (SWX: RLF) (OTCQB: RLFTF) is making a powerful move up the charts in recent days as heavy buying comes in from Switzerland. Big things are happening at Relief Therapetuics as CEO Jack Weinstein makes a presentation at the German Equity Forum #EKF20 in the Oslo virtual room to discuss the clinical progress of Relief’s main compound #RLF100 as a potentially transformative therapeutic option for critical #COVID19.
RLF: RLFTF is among the most exciting and dynamic stories on the OTCQB that has become the darling of small caps as its wunderdrug Aviptadil continues to demonstrate very positive results in the fight against coronavirus (COVID-19) with no other therapeutic in trials having the success rate of RLF-100. A growing number of cases treated with Aviptibile are leading to rapid recovery from respiratory in patients critically ill from coronavirus and its being picked up by mainstream press.
Relief Therapeutics Holding AG (SWX: RLF) (OTCQB: RLFTF) operating out of Radnor, Pennsylvania. and Geveva, Switzerland is founded by former Merck executives and primarily focused on clinical-stage programs based on molecules of natural origin (peptides and proteins) with a history of clinical testing and use in human patients or a strong scientific rationale. Currently, Relief is concentrating its efforts on developing new treatments for respiratory disease indications. Relief holds orphan drug designations from the U.S. FDA and the European Union for the use of VIP to treat ARDS, pulmonary hypertension, and sarcoidosis. Relief also holds a patent issued in the U.S. and multiple other countries covering potential formulations of RLF-100™. Relief Therapeutics is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on the OTCQB under the symbol RLFTF.
Relief Therapeutics lead candidate is RLF-100™ (Aviptadil); is a synthetic formulation of Vasoactive Intestinal Polypeptide (VIP) which is known to be produced throughout the body and to be primarily concentrated in the lungs. Vasoactive Intestinal Peptide has demonstrated an immediate clinical response in some patients with COVID-19 respiratory failure. A response of this magnitude has previously not been seen with an antiviral agent and is akin to the first reports of penicillin in treating pneumococcal pneumonia. Similar results have been demonstrated in acute respiratory distress syndrome caused by sepsis.
Aviptadil has been granted FDA Fast Track Designation and emergency IND authorization and inhaled delivery of RLF-100™ for the treatment of Critical COVID-19 with respiratory. RLF-100™ is being investigated in two placebo-controlled US Phase 2b/3 clinical trials in respiratory deficiency due to COVID-19. Since July 2020, more than 210 patients with Critical COVID-19 and Respiratory Failure have been treated with RLF-100™ under FDA-approved protocols.
Relief is led by CEO Jack Weinstein. He brings over 40 years of wide-ranging executive management expertise, including as a CFO, investment banker and consultant in the biopharmaceutical and life sciences industries. Jack has extensive experience in finance and healthcare investment banking, corporate and business development as well as FDA regulatory and intellectual property strategies. He holds an MBA from Harvard University. Relief’s Chief Scientific Officer. Dr. Jonathan C. Javitt is deeply connected with the FDA. He is doing all of the right things to set Aviptadil up for approval.
To Find out the inside Scoop on Relief Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
Relief Therapeutics partner; NeuroRx is led by former senior executives of Johnson & Johnson, Eli Lilly, Pfizer, and AstraZeneca, PPD. In addition to its work on RLF-100™, NeuroRx has been awarded Breakthrough Therapy Designation and a Special Protocol Agreement to develop NRX-101 in suicidal bipolar depression and is currently in Phase 3 trials. Its executive team is led by Prof. Jonathan C. Javitt, MD, MPH, who has served as a health advisor to four Presidential administrations and worked on paradigm-changing drug development projects for Merck, Allergan, Pharmacia, Pfizer, Novartis, and Mannkind, together with Robert Besthof, MIM, who served as the Global Vice President (Commercial) for Pfizer’s Neuroscience and Pain Division.
On November 13 Relief Therapeutics and NeuroRx announced that as of today, 150 patients (out of a targeted enrollment of 165) have been enrolled in the ongoing phase 2b/3 trial of RLF-100™ (aviptadil) for treating respiratory failure in patients with Critical COVID-19. Respiratory failure is defined, according to FDA guidance, as the need for intensive care with mechanical ventilation, non-invasive ventilation, or high-flow nasal oxygen in order to sustain adequate levels of blood oxygen. So far, no drug-related Serious Adverse Events have been reported.
There is currently no FDA-approved drug that has shown efficacy in patients who are already in the Intensive Care Unit (ICU) with Respiratory Failure. Although NeuroRx and Relief are optimistic that RLF-100™ will also be effective in treating early COVID-19, the companies have focused first on those patients who have no available therapy and are at the highest risk of mortality. An open-label prospective study in patients with Critical COVID-19 has already shown a nine-fold hazard ratio advantage in both survival and recovery from respiratory failure with both statistically significant (P < .001). More than 110 patients with similar severity have additionally been treated nationwide under an FDA-sanctioned Expanded Access Protocol (NCT04453839).
Although the phase 2b/3 study remains blinded, illustrative blinded recoveries from signs of Critical COVID-19 on Chest x-ray within 10 days have been reported by study sites and shared with the study’s Data Monitoring Committee and FDA (see figure). Until the study is unblinded, it cannot be known whether this rapid recovery was more frequent among patients treated with RLF-100™ compared to those treated with placebo. However, in the open-label prospective study, more rapid recovery was seen among 21 patients treated with RLF-100TM than those treated with standard of care with an average of nine fewer ICU days in the RLF-100TM treated patients compared to those treated with Standard of Care.
Completion of enrollment is anticipated in the coming weeks. Enrollment was uniquely challenged by the devastating effects of the pandemic. It strained the capacity of hospitals and caused the temporary incapacity of investigators and study coordinators at several study sites, who themselves contracted COVID-19 in the course of their duties.
Prof. Jonathan Javitt, CEO and founder of NeuroRx, Inc stated: “Should RLF-100™ prove to be safe and effective for treating COVID-19 Respiratory Failure, the nation will owe an eternal debt of gratitude to the front-line healthcare workers, technicians, study coordinators, nurses, and doctors who worked seven days a week to help develop this treatment while risking their own health to do so. They are the true heroes.”
With more #COVID19 cases, the enrollment for phase 2b/3 trial of #RLF-100 ™ (#aviptadil) is picking up. Main shareholder also excercising most of the remaining warrants. $RLF $RLFTFhttps://t.co/6mwX6O1tNc
— Lehner (@StefanLehner) November 13, 2020
For more on Relief Therepuetics Subscribe Right Now!
Relief Therapeutics is making a powerful move up the charts in recent days as heavy buying comes in from Switzerland. Big things are happening at Relief Therapetuics as CEO Jack Weinstein makes a presentation at the German Equity Forum #EKF20 in the Oslo virtual room to discuss the clinical progress of Relief’s main compound #RLF100 as a potentially transformative therapeutic option for critical #COVID19. RLF: RLFTF is among the most exciting and dynamic stories on the OTCQB that has become the darling of small caps as its wunderdrug Aviptadil continues to demonstrate very positive results in the fight against coronavirus (COVID-19) with no other therapeutic in trials having the success rate of RLF-100. A growing number of cases treated with Aviptibile are leading to rapid recovery from respiratory in patients critically ill from coronavirus and its being picked up by mainstream press. Microapdaily has been reporting on RLF since $0.05. We will be updating on Relief on a daily basis so make sure you are subscribed to microcapdaily.com so you know what is going on with Relief.
Sign Up now for our 100% FREE Penny Stock Newsletter
Disclosure: we hold no position in Relief either long or short and we have not been compensated for this article.